2. Search Result
Search Result
Results for "

mouse skeletal muscles

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

1

Peptides

9

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0470
    Neomycin sulfate
    65+ Cited Publications

    		 Environmental Pollutants Antibiotic Phospholipase Bacterial Infection Metabolic Disease Cancer
    Neomycin sulfate, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin sulfate is a known phospholipase C (PLC) inhibitor. Neomycin sulfate potently inhibits both the nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis. Neomycin sulfate inhibits IP3-mediated Ca 2+ release, MgATP-dependent Ca 2+ uptake, and electrical excitation-evoked skeletal muscle Ca 2+ transients. Neomycin sulfate depletes gut microbiota in specific mouse models, causes hearing impairment, and kidney damage with prolonged exposure. Neomycin sulfate can be used for the research of cancer .
    Neomycin sulfate
  • HY-12546
    Brevetoxin B

    Brevetoxin-2; PbTx-2

    		 Sodium Channel Apoptosis Calcium Channel Potassium Channel Caspase Neurological Disease Cancer
    Brevetoxin B (Brevetoxin-2) is a red tide toxin. Brevetoxin B affects sodium, potassium and calcium currents in nerve terminals. Brevetoxin B also modulates the metabolic activity of Jurkat cells, reduces cell viability and induces apoptosis. Brevetoxin B can be used in research on synaptic transmission and tumors .
    Brevetoxin B
  • HY-135190
    (-)-Cedrene
    2 Publications Verification

    α-cedrene

    		 Environmental Pollutants Bacterial Infection Metabolic Disease Cancer
    (-)-Cedrene (α-cedrene) is a major constituent that can be found in essential oils. (-)-Cedrene (α-cedrene) is a natural, orally active ligand of mouse olfactory receptor 23, which induces skeletal muscle hypertrophy in mice. (-)-Cedrene exhibits trypanocidal (Trypanosoma b. brucei) (IC50 = 4.07 μg/mL). (-)-Cedrene is antileukemic in vitro (IC50 = 22.2 μg/mL). (-)-Cedrene has antimicrobial activity against anaerobic bacteria and yeast. (-)-Cedrene exhibits anti-obesity activity .
    (-)-Cedrene
  • HY-150520
    Neomycin

    		Antibiotic Phospholipase Infection Cancer
    Neomycin, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin is a known phospholipase C (PLC) inhibitor. Neomycin potently inhibits both the nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis. Neomycin inhibits IP3-mediated Ca 2+ release, MgATP-dependent Ca 2+ uptake, and electrical excitation-evoked skeletal muscle Ca 2+ transients. Neomycin depletes gut microbiota in specific mouse models, causes hearing impairment, and kidney damage with prolonged exposure. Neomycin can be used for the research of cancer .
    Neomycin
  • HY-I0501
    2'-Aminoacetophenone

    o-aminoacetophenone

    		 Bacterial Apoptosis Atg8/LC3 p62 Autophagy Infection Inflammation/Immunology
    2'-Aminoacetophenone is an orally active inducer of apoptosis and respiratory biomarker. 2'-Aminoacetophenone can be used to detect Pseudomonas aeruginosa infections in the lungs of cystic fibrosis patients. 2'-Aminoacetophenone can inhibit the protein levels of LC3BII and p62 in macrophages infected with pqsA or mvfR and regulate autophagy. 2'-Aminoacetophenone can disrupt mitochondrial function by inducing oxidative stress and apoptosis signaling, leading to dysfunction in mouse skeletal muscle .
    2'-Aminoacetophenone
  • HY-178281
    E0199

    		Potassium Channel Sodium Channel Neurological Disease
    E0199 is a novel potent dual-target KV7/NaV modulator that activates the KV7 channel (KV7.2/7.3 (EC50 = 12.78 nM), KV7.2 (EC50 = 0.50 μM), and KV7.5 (EC50 = 27.14 nM) channels) while simultaneously blocks the NaV1.7 (IC50 = 0.52 μM), NaV1.8 (IC50 = 0.24 μM), and NaV1.9 (IC50 = 0.16 μM) channels. E0199 shows a potent analgesic effect without affecting heart and skeletal muscle ion channels critically in a chronic constriction injury (CCI) mouse model. E0199 can be used for Neuropathic pain (NP) research .
    E0199
  • HY-121811
    Pongamol

    Lanceolatin C

    		 Glycosidase Phosphatase Interleukin Related TNF Receptor COX Beclin1 GLUT FAK Akt mTOR p38 MAPK Keap1-Nrf2 Apoptosis Amyloid-β Tau Protein Autophagy Neurological Disease Inflammation/Immunology Cancer
    Pongamol (Lanceolatin C) is an orally active flavonoid with an IC50 of 75 μM and a Ki of 58 μM against PTPase-1B, and an IC50 of 103.5 μM against intestinal α-Glycosidase. Pongamol reduces the release of IL‑1β, TNF‑α, COX‑2 and iNOS in cells, reverses the nuclear translocation of NF‑κB, and upregulates the levels of Beclin 1 and LC3 Ⅱ/LC3 Ⅰ. Pongamol promotes glucose uptake by increasing the level of GLUT4 on the surface of skeletal muscle cells. Pongamol inhibits epithelial-mesenchymal transition by suppressing the FAK/Akt-mTOR signaling pathway. Pongamol inhibits neuronal cytotoxicity, suppresses cell apoptosis and extends the lifespan of Caenorhabditis elegans by activating the MAPKs/Nrf2 signaling pathway. Pongamol exerts hypoglycemic effects in diabetic mouse models. Pongamol exhibits antibacterial activity. Pongamol alleviates oxidative stress, neuroinflammation, Aβ deposition and excessive phosphorylation of Tau Protein, and restores autophagy function in Alzheimer's disease mouse models by inhibiting the Akt/mTOR signaling pathway. Pongamol is applicable to research related to Alzheimer's disease, type 2 diabetes, non-small cell lung cancer and postprandial hyperglycemia .
    Pongamol
  • HY-W023323
    (S)-β-Aminoisobutyric acid hydrochloride
    1 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    (S)-β-Aminoisobutyric acid hydrochloride is a cytoprotective agent, which is a non-proteinogenic amino acid enantiomer derived from valine metabolism in skeletal muscle mitochondria. The plasma level of (S)-β-Aminoisobutyric acid hydrochloride increases significantly after acute aerobic exercise (and is not affected by the AGXT2 rs37369 genotype), and it is secreted by mouse extensor digitorum longus and soleus muscles in ex vivo contraction assays. (S)-β-Aminoisobutyric acid hydrochloride specifically protects osteocytes from oxidative stress-induced cell death .
    (S)-β-Aminoisobutyric acid hydrochloride
  • HY-135000
    Decarbamoylsaxitoxin

    DcSTX; DecarbamoylSTX

    		 Endogenous Metabolite Drug Metabolite Neurological Disease
    Decarbamoylsaxitoxin is a sodium channel inhibitor that blocks the influx of sodium ions through the membranes of excitable nerves and skeletal muscle cells, thereby preventing the formation of action potentials. Decarbamoylsaxitoxin is an acidic hydrolysis product of saxitoxin, and its toxic effects on mice are identical to those of saxitoxin. Decarbamoylsaxitoxin inhibits veratridine- and ouabain-induced swelling and lysis of mouse neuroblastoma cells by blocking Na + channels. Decarbamoylsaxitoxin can be used in studies related to paralytic shellfish poisoning .
    Decarbamoylsaxitoxin
  • HY-I0501R
    2'-Aminoacetophenone (Standard)

    o-aminoacetophenone (Standard)

    		 Reference Standards Bacterial Apoptosis Atg8/LC3 p62 Autophagy Infection Inflammation/Immunology
    2'-Aminoacetophenone (Standard) is the analytical standard of 2'-Aminoacetophenone. This product is intended for research and analytical applications. 2'-Aminoacetophenone is an orally active inducer of apoptosis and respiratory biomarker. 2'-Aminoacetophenone can be used to detect Pseudomonas aeruginosa infections in the lungs of cystic fibrosis patients. 2'-Aminoacetophenone can inhibit the protein levels of LC3BII and p62 in macrophages infected with pqsA or mvfR and regulate autophagy. 2'-Aminoacetophenone can disrupt mitochondrial function by inducing oxidative stress and apoptosis signaling, leading to dysfunction in mouse skeletal muscle .
    2'-Aminoacetophenone (Standard)
  • HY-N11262
    Sudachitin

    		Phosphodiesterase (PDE) Sirtuin PGC-1α p38 MAPK HSP TNF Receptor NO Synthase Apoptosis Metabolic Disease Inflammation/Immunology
    Sudachitin is an orally active compound that potently inhibits mouse PDE1C and human PDE4B, with IC50 values of 5.0 μM and 15.0 μM, respectively. Sudachitin upregulates Sirt1 and PGC‑1α expression in skeletal muscle to regulate energy metabolism and promote mitochondrial biogenesis. Sudachitin improves lipid metabolism, glucose tolerance, insulin sensitivity, energy expenditure, and fatty acid β‑oxidation. Sudachitin activates p38MAPK signaling, induces HSP27 phosphorylation and caspase‑dependent apoptosis, and blocks EGF‑driven keratinocyte migration and proliferation. Sudachitin suppresses LPS‑induced TNF‑α, NO, and iNOS expression in macrophages and shows potent anti‑inflammatory activity. Sudachitin can be used for the research of metabolic syndrome, type 2 diabetes, and psoriasis. .
    Sudachitin
  • HY-117356A
    MRS2693 ammonium

    		P2Y Receptor NF-κB ERK Apoptosis Inflammation/Immunology
    MRS2693 ammonium is the ammonium dalt form of MRS2693 (HY-117356). MRS2693 ammonium is a selective agonist for P2Y6 with an EC50 of 0.015 μM. MRS2693 ammonium protects C2C12 skeletal muscle cells from TNFα-induced apoptosis. MRS2693 ammonium reduces the activation of NF-kB, activates the ERK1/2 pathway, and has a cytoprotective effect on mouse ischemia-reperfusion injury model [2].
    MRS2693 ammonium
  • HY-117356B
    MRS2693 trisodium

    		P2Y Receptor NF-κB ERK Cardiovascular Disease
    MRS2693 trisodium is a selective P2Y6 agonist with an EC50 value of 0.015 μM. MRS2693 trisodium can reduce the activation of NF-kappaB and activate the ERK1/2 pathway, and has a cytoprotective effect on mouse hindlimb skeletal muscle ischemia-reperfusion injury model .
    MRS2693 trisodium
  • HY-120974
    α-lipoic acid derivative 1

    		GLUT Metabolic Disease
    α-Lipoic Acid Derivative 1 (Compound AN-7) is an α-lipoic acid derivative that enhances glucose transport in skeletal muscle by releasing active α-lipoic acid (LA), significantly improving glucose metabolism. In L6 skeletal muscle cells, α-Lipoic Acid Derivative 1 significantly increases glucose transport rates, approximately 12 times more potent than the parent compound α-lipoic acid (HY-N0492). In a mild diabetic mouse model, 10 mg/kg of α-Lipoic Acid Derivative 1 administered for two weeks significantly reduced blood glucose levels by 39%. α-Lipoic Acid Derivative 1 shows significant potential in research related to glucose metabolism in diabetes .
    α-lipoic acid derivative 1
  • HY-135190R
    (-)-Cedrene (Standard)

    α-cedrene (Standard)

    		 Bacterial Reference Standards Infection Metabolic Disease Cancer
    (-)-Cedrene (α-cedrene) (Standard) is the analytical standard of (-)-Cedrene. This product is intended for research and analytical applications. (-)-Cedrene is a major constituent that can be found in essential oils. (-)-Cedrene (α-cedrene) is a natural, orally active ligand of mouse olfactory receptor 23, which induces skeletal muscle hypertrophy in mice. (-)-Cedrene exhibits trypanocidal (Trypanosoma b. brucei) (IC50 = 4.07 μg/mL). (-)-Cedrene is antileukemic in vitro (IC50 = 22.2 μg/mL). (-)-Cedrene has antimicrobial activity against anaerobic bacteria and yeast. (-)-Cedrene exhibits anti-obesity activity .
    (-)-Cedrene (Standard)
  • HY-183626
    TM5614 sodium

    		PAI-1 Ser/Thr Protease Furin MMP Notch Apoptosis Inflammation/Immunology Cancer
    TM5614 sodium is an orally active and specific PAI-1 inhibitor with an IC50 of <6.95 μM. TM5614 sodium blocks the interaction between PAI-1 and serine proteases or LRP-1, and enhances plasmin generation. TM5614 sodium restores macrophage efferocytosis and promotes macrophage polarization. TM5614 sodium alleviates PAI-1-mediated inhibition of Furin, promotes MT1-MMP maturation, activates the NOTCH1 signaling pathway, inhibits proliferation and induces apoptosis. TM5614 sodium promotes skeletal muscle regeneration and alleviates inflammation in a mouse model of skeletal muscle injury. TM5614 sodium can be used in research on skeletal muscle injury-induced inflammation and chronic myeloid leukemia .
    TM5614 sodium
  • HY-165486
    AWD 122-60

    		Potassium Channel Calcium Channel Cardiovascular Disease
    AWD 122-60 is a potassium channel blocker and calcium sensitizer, with IC50 values of 11 μM and 29 μM, respectively, against mouse skeletal muscle ATP-sensitive potassium (KATP) channels. AWD 122-60 exerts potent positive inotropic activity. AWD 122-60 exhibits antiarrhythmic activity in vivo and prolongs myocardial refractory period in vitro. AWD 122-60 can be used for research related to arrhythmias .
    AWD 122-60
  • HY-121554
    Kojic amine

    		GABA Receptor Neurological Disease
    Kojic amine is an orally active γ-aminobutyric acid (GABA) analog. Kojic amine acts as a GABA mimic that inhibits sodium-independent [ 3H]GABA binding to rat brain cell membranes. Kojic amine reduces flexor spasms in chronic spinal rat and cat models. Kojic amine prevents tonic extensor convulsions in mice. Kojic amine produces a transient, dose-dependent analgesic effect in the mouse hot-plate test. Kojic amine can be used in research related to skeletal muscle spasm, epilepsy and analgesia [1][2]
    Kojic amine
  • HY-P11741
    BV2

    		Exosomes Biochemical Assay Reagents Neurological Disease
    BV2 is a delivery peptide that binds to BVES, with a Ka of 2.03 μM for the BVES target. BV2 specifically binds to the extracellular domain of BVES, achieving muscle homing and cellular internalization via caveolae-mediated endocytosis. When BV2 is modified on the surface of exosomes by PMO, it enhances dystrophin restoration in the peripheral muscles and myocardium of dystrophin-deficient mice. BV2 is applicable to research related to Duchenne muscular dystrophy and muscle atrophy .
    BV2
  • HY-115549
    AMPK activator 18

    		AMPK Acetyl-CoA Carboxylase Metabolic Disease
    AMPK activator 18 is a potent allosteric activator of AMPK complexes containing the β2 isoform. AMPK activator 18activates α2-containing AMPK α2β2γ1 and α2β2γ3 complexes, with EC50 values of 17.2 and 82.1 nM. AMPK activator 18 stimulates β2-AMPK in cells, and glucose uptake by isolated skeletal muscle. AMPK activator 18 induces acetyl-coenzyme A carboxylase (ACC) and AMPK α-T172 phosphorylation. AMPK activator 18 can be used for the research of type 2 diabetes .
    AMPK activator 18
  • HY-182487
    Deoxaphomin

    		Arp2/3 Complex Inflammation/Immunology
    Deoxaphomin is a cytochalasin. Deoxaphomin inhibits Actin filament elongation and reduces the viscosity of polymerized actin filaments. Deoxaphomin induces rounding of fibroblasts, contraction of actin cables, formation of actin-containing hairy structures, and formation of actin-containing cytoplasmic rodlets in fibroblasts. Deoxaphomin inhibits membrane ruffling in fibroblasts and capping in lymphocytes .
    Deoxaphomin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: